Therapeutic agent for cancer
US7700546B2 · kind B2 · utility
6Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 20, 2006 |
| Grant date | Apr 20, 2010 |
| Priority date | — |
| Expiry date | Jun 20, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a cancer therapeutic agent containing as an active ingredient a substance, particularly CRM197 which inhibits the binding of HB-EGF to EGF receptor by binding to HB-EGF, wherein a cancer is selected from the group consisting of a bladder cancer, a colon cancer or peritoneal metastatic cancers of a stomach cancer and a pancreatic cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.